Form 4: Northrop Grumman Executive's Equity Transactions

Sentiment:

Insider Transaction Report


Northrop Grumman's CVP & President of Aeronautics Systems, Thomas H. Jones, reported the acquisition of common stock and new grants of restricted performance and stock rights.

Summary

  • Thomas H. Jones, CVP & President of Aeronautics Systems at Northrop Grumman Corp (NOC), reported equity transactions on February 11, 2026.
  • Acquired 6,910.12 shares of common stock upon the settlement of Restricted Performance Stock Rights (RPSRs).
  • Disposed of 3,059 shares of common stock at a price of $678.83 per share, likely for tax withholding purposes related to the RPSR settlement.
  • Received new grants of 5,927.12 Restricted Performance Stock Rights (RPSRs) under the 2024 Long-Term Incentive Stock Plan (LTISP), with a measurement period ending on December 31, 2028.
  • Received new grants of 1,701 Restricted Stock Rights (RSRs) under the 2024 LTISP, which are scheduled to vest on February 12, 2029.
  • The settlement of 2023 RPSRs, with a measurement period ending December 31, 2025, resulted in the issuance of shares at 148% of the target award.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive filing, reflecting successful achievement of performance targets for prior awards and continued alignment of executive incentives with future company performance through new equity grants.

Positives

  • The settlement of 2023 Restricted Performance Stock Rights (RPSRs) at 148% of the target award indicates strong performance against established metrics.
  • New grants of Restricted Performance Stock Rights and Restricted Stock Rights align executive incentives with Northrop Grumman's long-term performance and shareholder value creation.

Negatives

  • The disposal of 3,059 shares of common stock, likely for tax withholding, reduces the executive's direct shareholding.

Risks

  • Restricted Performance Stock Rights (RPSRs) are contingent on future performance metrics, meaning the actual number of shares received can vary based on company achievement.
  • Restricted Stock Rights (RSRs) and RPSRs are subject to future vesting conditions, which could be forfeited if employment terms are not met or performance targets are not achieved.

Future Outlook

The executive's compensation structure, including new grants of Restricted Performance Stock Rights and Restricted Stock Rights, is designed to align future incentives with Northrop Grumman's long-term performance and shareholder value creation through measurement periods extending to December 31, 2028, and vesting dates up to February 12, 2029.

Industry Context

StockSavvy.ai notes that executive equity grants, particularly those tied to performance metrics, are a standard practice in the defense and aerospace industry to incentivize long-term leadership and align executive interests with shareholder returns. The settlement at 148% of target for the 2023 RPSRs suggests strong operational execution within the Aeronautics Systems division, a key segment for Northrop Grumman, especially given the competitive landscape with peers like Lockheed Martin and Boeing.

Comparison to Industry Standards

  • The settlement of Restricted Performance Stock Rights at 148% of the target award indicates robust performance, potentially outperforming typical industry average achievement rates for similar long-term incentive plans.
  • Many companies in the defense sector, such as Lockheed Martin and Raytheon Technologies, utilize similar performance-based equity awards, where achieving above-target results is a strong indicator of operational success and strategic execution.
  • The structure of these grants, with multi-year vesting and performance periods, is consistent with best practices for executive compensation in large, complex industrial sectors.

Stakeholder Impact

  • Shareholders: Executive's interests are further aligned with shareholder value through performance-based equity, potentially leading to improved long-term company performance.
  • Employees: The executive's compensation structure and achievement of performance targets may serve as a benchmark or motivator for other employees within the company.

Next Steps

  • Continued vesting of existing Restricted Stock Rights (RSRs) and Restricted Performance Stock Rights (RPSRs) through 2029.
  • Future measurement and settlement of RPSRs based on performance metrics for the respective measurement periods.

Key Dates

DateDescription
02/16/2023Grant date for 2023 RPSRs and RSRs under the 2011 Long-Term Incentive Stock Plan (LTISP).
02/14/2024Grant date for RPSRs and RSRs under the 2011 LTISP.
02/18/2025Grant date for RPSRs and RSRs under the 2024 LTISP.
12/31/2025Measurement period end for 2023 RPSRs.
02/11/2026Transaction date for reported acquisitions and dispositions; grant date for new RPSRs and RSRs under the 2024 LTISP.
02/13/2026Signature date of the filing.
02/17/2026Vesting date for 2023 RSRs.
12/31/2026Measurement period end for 2024 RPSRs.
02/16/2027Vesting date for 2024 RSRs.
12/31/2027Measurement period end for 2025 RPSRs.
02/18/2028Vesting date for 2025 RSRs.
12/31/2028Measurement period end for 2026 RPSRs.
02/12/2029Vesting date for 2026 RSRs.

Recommendation

hold

This Form 4 filing details routine executive compensation activities, including the settlement of performance-based awards and new equity grants. While the achievement of 148% of target for prior performance awards is positive, indicating strong operational execution, these transactions are standard for executive incentive plans and do not provide new fundamental information to warrant a change in investment recommendation. The filing reinforces the alignment of executive incentives with long-term company performance, supporting a 'hold' stance for investors already positioned in Northrop Grumman.

Keywords

Northrop Grumman, NOC, Form 4, Insider Trading, Executive Compensation, Restricted Stock, Performance Shares, Equity Grant, Corporate Governance

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.